The Breakthrough Leadership Team has dedicated their careers to the investment, construction and operations of best-in-class life science real estate. 

headshot of Dan Belldegrun, Chief Executive Office and Co-Founder of Breakthrough Properties

Dan Belldegrun

Chief Executive Officer and Co-Founder
Dan D'Orazi

Daniel D’Orazi

EVP and Chief Investment Officer
headshot of Susie Harborth, Chief Business Officer

Susie Harborth

Chief Business Officer
headshot of Lesley Chao, Chief Financial Officer

Lesley Chao

Chief Financial Officer
headshot of Christian Heimple, SVP, Design & Construction

Christian Heimple

SVP, Design & Construction
headshot of Sabine Heller, SVP and Chief Experience Officer

Sabine Heller

SVP and Chief Experience Officer
headshot of Aaron Kazam, SVP, Acquisitions

Aaron Kazam

SVP, Acquisitions
Tom Renn

Thomas Renn

SVP, Acquisitions & Development, Europe
Jenni Warne

Jennifer Warne

SVP, Legal and Chief Compliance Officer
headshot of Peter Oden, VP, Portfolio Management

Peter Oden

VP, Portfolio Management
Breakthrough Properties is backed by a joint venture between Tishman Speyer and Bellco Capital.
Rob Speyer
Rob Speyer
Tishman Speyer
President and Chief Executive Officer
Arie Belldegrun
Arie Belldegrun, M.D.
Bellco Capital
Chairman
Rebecka Belldegrun
Rebecka Belldegrun, M.D.
Bellco Capital
Founder and Chief Executive Officer
headshot of Paul Galiano, Tishman Speyer Senior Managing Director, Co-Head of U.S. Acquisitions
Paul Galiano
Tishman Speyer
Senior Managing Director, Co-Head of U.S. Acquisitions
Joseph Doran
Joseph Doran
Tishman Speyer
Senior Managing Director, Chief Financial Officer
Joshua Kazam
Joshua Kazam
Two River Group
Co-Founder and Partner
Michael Benner
Michael Benner
Tishman Speyer
Senior Managing Director, General Counsel
black and white photo of Josh Bradley in suit jacket
Josh Bradley
Bellco Capital
Chief Investment Officer

Scientific Advisory Board

Our world-renowned Scientific Advisory Board (“SAB”) of leading scientists, entrepreneurs, CEOs and venture capital investors bring their decades of experience to our unique platform for the benefit of our client-tenants.

Arie Belldegrun
Arie Belldegrun, M.D.
Executive Chairman and Co-Founder of Allogene, Chairman of Bellco Capital, Two River Group, UroGen Pharma and Kronos Bio
Franz Humer
Franz Humer, M.D.
Chairman of Humer Foundation, Former Chairman and CEO of Roche Holding
Liz Barrett
Liz Barrett
CEO of UroGen Pharma, Former CEO of Oncology at Novartis
Owen Witte
Owen N. Witte, M.D.
UCLA Professor of Microbiology, Immunology, and Molecular Genetics & President’s Chair of Development Immunology
David Chang
David Chang, M.D., PhD
Co-Founder and CEO of Allogene Therapeutics, Former Chief Medical Officer of Kite Pharma
Helen Kim
Helen Kim
Managing Director at Vida Ventures, Former Partner at Column Group and Executive Vice President of Business Development at Kite Pharma
Arjun Goyal
Arjun Goyal, M.D., MBA
Co-Founder and Managing Director at Vida Ventures, Former Investment Professional at 5AM Ventures
Stefan Vitorovic
Stefan Vitorovic
Co-Founder and Managing Director at Vida Ventures, Former Investment Professional at Third Rock
Ben Belldegrun
Ben Belldegrun
Managing Director and Founder of Pontifax AgTech, Former Portfolio Manager for Brevan Howard Asset Management
Amy Schulman
Amy Schulman
Managing Partner at Polaris Partners, Former general counsel at Pfizer and President, Pfizer Consumer Healthcare
Jakob Loven
Jakob Loven, PhD
Managing Partner at Nextech Invest; co-founder Relay Therapeutics (NASDAQ: RLAY) and Syros Pharmaceuticals (NASDAQ: SYRS)